L Catterton Partners entered into a definitive agreement to acquire Thorne HealthTech, Inc. from Mitsui & Co., Ltd., Kirin Holdings Company, Limited, Helsinn Therapeutics (U.S.), Inc., Diversified Natural Products, Inc. and others for approximately $620 million.
Transaction is subject to customary closing conditions, including satisfaction of the minimum tender condition, the waiting periods, if any, applicable to the Transactions pursuant to the HSR Act will have expired or otherwise been terminated and receipt of regulatory approvals. Thorne's independent Special Committee and Board of Directors have each unanimously approved the agreement and recommend that all stockholders tender their shares in the tender offer. Subject to the terms and conditions of the agreement, following the completion of the tender oer, L Catterton will acquire any shares of Thorne that are not tendered in the tender oer through a second-step merger for $10.20 per share in cash. Mitsui & Co. Ltd., Helsinn International (U.S.) Corporation, Diversified Natural Products, Inc., Kirin Holdings Company Limited and directors of Thorne, holding approximately 45% of the Company?s outstanding shares of Company Common Stock agreed to validly tender such shares. The board of directors of Purchaser have also approved the transaction. The transaction is expected to be completed in the fourth quarter of 2023.
CG Sawaya Partners (operating under Canaccord Genuity served as exclusive financial advisor and Rich Mullen of Wilson Sonsini Goodrich & Rosati served as legal advisor to Thorne and the Special Committee of the Board of Directors. BofA Securities served as financial advisor and Joshua Kogan, Ross M. Leff, Zoey Hitzert, Jason Kanner, Kathryn Keves Leonard, Vincent P. Thorn, Scott D. Price, Matthew Wood of Marshall P. Shaffer and Daniel Yip of Kirkland & Ellis LLP served as legal advisors to L Catterton. Ezra Borut and Morgan J. Hayes of Debevoise & Plimpton LLP acted as legal advisor to Mitsui & Co., Ltd. (TSE:8031).